

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Are Bogsnes

Application No.: To be assigned

Group Art Unit: To be assigned

Filed: November 20, 2003

Examiner: To be assigned

For: Novel Process For The Separation Of Proteins Using a Ca++ Containing Eluant

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. Copies of all references were either submitted to, or cited by, the Patent Office in parent application USSN 09/290,856 filed on April 13, 1999 and continuation application USSN 09/633,526.


The references are as follows:

1. U.S. Patent 5,633,350
2. U.S. Patent 3,649,456
3. U.S. Patent 6,214,547
4. U.S. 2002/0160955A1
5. EP 0195691
6. Konrad, Annals of the New York Academy of Sciences (1983) 413:12-22

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due. However, please charge any fees should they be required, to Novo Nordisk Pharmaceuticals, Inc. Deposit Account No. 14-1447.


Respectfully submitted,



Reza Green, Reg. No. 38,475

Novo Nordisk Pharmaceuticals, Inc.  
100 College Road West  
Princeton, NJ 08540  
(609) 987-5800

Date: November 20, 2003



Use the following customer number for all correspondence regarding this application.

23650  
PATENT TRADEMARK OFFICE

FORM PTO-1449 (Rev. 2-32)	U. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Atty. Docket No. 5432.220-US	Serial No. To be assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)		Applicant: Are Bogsnes	
		Filing Date November 20, 2003?	Group to be assigned

**U. S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		3,649,456	03/14/72	Benneville et al.	195	66	
		5,633,350	05/27/97	Fischer et al.	530	381	
		6,214,547	04/2001	Kjeldsen et al.	435	6	
		2002/0160955A 1	10/2001	Dubaquic et al.	514	12	

**FOREIGN PATENT DOCUMENTS**

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

Konrad, Annals of the New York Academy of Sciences (1983) 413:12-22

**EXAMINER** \_\_\_\_\_ **DATE CONSIDERED** \_\_\_\_\_

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.